• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gene Therapy for Sickle Cell Disease-A Debt to Be Paid.

作者信息

Ozuah Philip O

机构信息

Albert Einstein College of Medicine and Montefiore Medicine, Bronx, New York.

出版信息

JAMA Pediatr. 2021 Jun 1;175(6):565-566. doi: 10.1001/jamapediatrics.2020.7147.

DOI:10.1001/jamapediatrics.2020.7147
PMID:33749705
Abstract
摘要

相似文献

1
Gene Therapy for Sickle Cell Disease-A Debt to Be Paid.镰状细胞病的基因治疗——有待偿还的债务。
JAMA Pediatr. 2021 Jun 1;175(6):565-566. doi: 10.1001/jamapediatrics.2020.7147.
2
[Genetic conservation of sickle cell trait].[镰状细胞性状的遗传保守性]
Ann Soc Belg Med Trop (1920). 1955 Dec 31;35(6):649-60.
3
Therapeutic strategies in Sickle Cell Anemia: The past present and future.镰状细胞贫血的治疗策略：过去、现在与未来
Life Sci. 2017 Jun 1;178:100-108. doi: 10.1016/j.lfs.2017.03.025. Epub 2017 Apr 20.
4
Genetic Therapies for Sickle Cell Disease.镰状细胞病的基因疗法
Pediatr Clin North Am. 2018 Jun;65(3):465-480. doi: 10.1016/j.pcl.2018.01.008.
5
Acceptability of prenatal diagnosis by a sample of parents of sickle cell anemia patients in Cameroon (sub-Saharan Africa).喀麦隆（撒哈拉以南非洲地区）镰状细胞贫血患者家长样本对产前诊断的接受度。
J Genet Couns. 2011 Oct;20(5):476-85. doi: 10.1007/s10897-011-9372-y. Epub 2011 May 21.
6
Gene Therapy in a Patient with Sickle Cell Disease.镰状细胞病患者的基因治疗
N Engl J Med. 2017 May 25;376(21):2093-4. doi: 10.1056/NEJMc1704009.
7
Gene Therapy in a Patient with Sickle Cell Disease.镰状细胞病患者的基因治疗
N Engl J Med. 2017 May 25;376(21):2094. doi: 10.1056/NEJMc1704009.
8
Bone marrow transplantation (BMT) and gene replacement therapy (GRT) in sickle cell anemia.镰状细胞贫血的骨髓移植（BMT）和基因替代疗法（GRT）。
Niger J Med. 2008 Jul-Aug;17(3):251-6. doi: 10.4314/njm.v17i3.37390.
9
Rounding up sickle cells with gene therapy.用基因疗法围剿镰状细胞。
Sci Transl Med. 2017 Mar 15;9(381). doi: 10.1126/scitranslmed.aam9864.
10
Gene therapy in sickle cell disease: Possible utility and impact.镰状细胞病的基因治疗：潜在效用与影响
Cleve Clin J Med. 2020 Jan;87(1):28-29. doi: 10.3949/ccjm.87a.19124. Epub 2020 Jan 2.

引用本文的文献

1
Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.权衡利弊：关于遗传性血液疾病基因和细胞疗法伦理与社会层面的系统评价
BMC Med Ethics. 2025 Mar 14;26(1):36. doi: 10.1186/s12910-025-01188-3.
2
CRISPR technology in human diseases.用于人类疾病治疗的CRISPR技术。
MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug.
3
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.
镰状细胞病与不孕风险：对受影响女孩和妇女咨询与护理的启示
Expert Rev Hematol. 2024 Aug;17(8):493-504. doi: 10.1080/17474086.2024.2372320. Epub 2024 Jun 26.
4
Life after sickle cell disease, is it really uhuru?镰状细胞病后的生活，真的是自由了吗？
Lancet Haematol. 2023 Dec;10(12):e946-e949. doi: 10.1016/S2352-3026(23)00306-X.
5
A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America.用于估计美国镰状细胞病患者新疗法价值的健康经济评估模型框架
Pharmacoecon Open. 2023 Mar;7(2):313-320. doi: 10.1007/s41669-023-00390-6. Epub 2023 Feb 11.
6
Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study.非老年商业保险个体中与镰状细胞病相关的合并症患病率：一项回顾性队列研究。
PLoS One. 2022 Nov 29;17(11):e0278137. doi: 10.1371/journal.pone.0278137. eCollection 2022.
7
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.非老年商业保险个体中镰状细胞病的终身医疗费用。
Blood Adv. 2023 Feb 14;7(3):365-374. doi: 10.1182/bloodadvances.2021006281.
8
A landscape analysis and discussion of value of gene therapies for sickle cell disease.镰状细胞病基因治疗的价值分析与探讨。
Expert Rev Pharmacoecon Outcomes Res. 2022 Sep;22(6):891-911. doi: 10.1080/14737167.2022.2060823. Epub 2022 Apr 18.
9
Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.体外交错编辑：用于β-地中海贫血症细胞治疗的体外基因修饰。
Mol Ther. 2021 Nov 3;29(11):3163-3178. doi: 10.1016/j.ymthe.2021.10.002. Epub 2021 Oct 8.